A new method that improves the accuracy of interpreting blood pressure measurements taken at the ankle could be vital for individuals who are unable to have their blood pressure measured on the arm. A ...
Tetrandrine, a compound isolated from the root of a traditional Chinese medicine (TCM) Stephania tetrandra, has shown promise in combating Ebola virus infection in previous studies. Its precise ...
More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim is freshening up its leadership in the rare lung disease space with a newly ...
A New Hampshire Supreme Court Justice was found guilty of soliciting special treatment for her husband in a criminal grand jury investigation from the then-governor, NH Attorney General John Formella ...
The FDA has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis, a rare, progressive lung disease that can cause scarring and breathing difficulties. The approval marks the ...
University of Toronto researchers have made the first discovery of a virus that infects Legionella pneumophila, the bacteria that causes Legionnaires' disease. The findings, published in Science ...
Kidney Disease: Improving Global Outcomes (KDIGO) has issued comprehensive, evidence-based recommendations for clinicians managing immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis ...
A new study by researchers in Hungary has investigated whether DMT, a naturally occurring psychedelic compound, could protect brain cells from damage caused by stroke in animal models. The results ...
This image shows three brain cells with the faulty protein that causes Huntington’s disease. The bright yellow cell in the middle has built up a clump of this protein inside it. The blue spots in the ...
Immigrants come to the United States hale and healthy, but that doesn't last long, a new study says. Immigrants' heart disease risk increases the longer they live in the United States, research ...
A new treatment that proves to slow the progression of Huntington’s disease (HD) marks a breakthrough for a condition that has long been considered untreatable. Huntington’s is a rare, inherited ...
BARCELONA, Spain — In a noninferiority trial in pediatric-onset multiple sclerosis (POMS), ocrelizumab met its primary endpoint compared with fingolimod, demonstrating better tolerability and greater ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback